TY - JOUR T1 - Phosphorimidate Derivatives of Acyclovir; Antiviral Activity Against Canine Parvovirus <em>In Vitro</em> JF - bioRxiv DO - 10.1101/598177 SP - 598177 AU - Payal M Oak AU - Akash S. Mali AU - Atul R Chopade AU - Govind Shukla Y1 - 2019/01/01 UR - http://biorxiv.org/content/early/2019/04/03/598177.abstract N2 - Canine parvovirosis is a very transmissible, severe and often deadly infectious disease of dogs caused by Type II canine parvovirus (CPV-2). Recently shows that Parvoviruses are very resistant to Acyclovir which is often used for HSV Chemotherapy in humans and various virucidal purposes in animal diseases in veterinary clinics and animal housing facilities. If acquiescence with vaccination programs and with appropriate decontamination plans is guaranteed, there should be no continuous, nor common, CPV-2 outbreaks. However, a continuous spread of CPV-2 infections is observed, even in shelters where an appropriate vaccination program is applied, and this is reason to provide an antiviral drug therapy. The aim of the present study was to Development of antiviral drugs with determination the effect of concentration of new chemical entity and analyze Acyclovir analogous against CPV-2 strains. A sensitive in vitro assay capable of measuring the infectivity of CPV-2 was employed to determine the efficacy of three different concentrations of 9-(2-hydroxyethomethyl)guanine phosphoromonomorpholidate. We successfully show that new compounds inhibit CPV-2 replication with exhibiting 50% inhibitory concentrations (IC50s) in the low-micromolar range (50μM). ER -